Amarantus BioScience has appointed Dr Mark Benedyk to its board of directors.
Dr Benedyk has served as a corporate adviser to the US-based biotech since 2011, supporting its research into conditions associated with neurodegeneration and apoptosis.
He currently serves as a managing partner at business consultancy Rila Partners in addition to being a member of the strategic advisory board at KemPharma and a director at the Center for Drug Research and Development Ventures.
Previous positions including serving as head of The Pfizer Incubator (TPI), a California-based business launched by Pfizer to help scientists with entrepreneurial ambitions to bring their medical innovations to patients.
Dr Benedyk has also held executive business development roles at Ascenta Therapeutics, Optimer Pharmaceuticals, Aurora Biosciences and Elan Pharmaceutical.
“I am excited to join the Amarantus board at such an important stage of the company’s scientific and business development growth,” said Dr Benedyk.
“I look forward to helping the company as it advances MANF [mesencephalic astrocyte neurotrophic factor] towards the clinic for Parkinson’s disease, and executes a commercial strategy for its promising clinical diagnostic tests for Parkinson’s and Alzheimer’s disease.”